Clinical trial
Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in…
NCT00038454 · Hemosol, Industry · Suspended
Key facts
| NCT number | NCT00038454 |
|---|---|
| Title | Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery |
| Official title | A Phase II, Randomized, Single-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink[Tm] (o-Raffinose Cross-Linked Human Hemoglobin) in Subjects Undergoing Primary Coronary Artery Bypass Grafting Surgery |
| Lead sponsor | Hemosol, Industry |
| Status | Suspended |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Hemolink (hemoglobin raffimer IV solution) |
| Enrollment | 180 |
| First posted | May 31, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: